Based on their analyses, researchers call for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2 to treat COVID-19 in its early stages
Fed to lab mice, the particles appeared to be nontoxic and had significant therapeutic effects
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.